FreeStyle Libre CGMs, a breakthrough in diabetes care, actually started as a failed product — but key changes made it the ...

On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

Opens in a new tab or window Abbott's FreeStyle Libre 2 and 3 are the first and only ... (The BMJ) Obesity treatments did not reduce other medical costs over 2 years, an analysis of U.S. health ...

Abbott's FreeStyle Libre 2 and 3 are the first and only patient-applied continuous ... (The BMJ) Obesity treatments did not ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as ... CGM if it is available for the same or lower acquisition cost, according to the draft, which is due to be finalised shortly.

Diabetes educators play an essential role in helping patients achieve optimal health outcomes through personalized support ...

Insulet’s PODD robust execution to expand the Omnipod 5 platform globally is a tailwind. The company is also capitalizing on the significant growth opportunities in the Type 2 diabetes space. PODD ...

"Scientifically, this did not make too much sense, but patients were bearing that burden of care, cost and inconvenience," he said. Now there is clear guidance for Freestyle Libre sensors. The recent ...

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), The Procter & ...

Health care apps like MyChart, mySugr, GoodRx, and Smoke Free can enhance patient care through accessibility, convenience, ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...